ANI Pharma Q2 revenue $266M (+25.9%), GAAP EPS $1.05, adjusted EPS $2.21

ANI PHARMACEUTICALS INC

2026-Q2 EPS reported $2.32 revenue$503,506,000

Q2 net revenue $266.0M, +25.9% YoY; GAAP net income $24.7M ($1.05/diluted) vs $8.1M prior year.
Cortrophin Gel revenue $117.1M, +43.5% YoY; ILUVIEN down 16.1% to $18.7M on shipment timing.
Adjusted non-GAAP EBITDA $71.6M (+32.4%); adjusted diluted EPS $2.21 vs $1.80 prior.
FY26 total revenue guidance reaffirmed $1,080-1,140M; Cortrophin Gel guidance narrowed to $520-540M from $540-575M.
Board authorized $100M share repurchase program through May 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.